[The interferon alfa-2a treatment of the severe form of the Kasabach-Merritt syndrome with neonatal onset].
González de Dios
J
J
Servicio de Pediatría, Hospital Universitario San Juan, Alicante.
Moya Benavent
M
M
Herranz Sánchez
Y
Y
Juste Ruiz
M
M
González Montero
R
R
D000208:Acute Disease; D003131:Combined Modality Therapy; D018450:Disease Progression; D004211:Disseminated Intravascular Coagulation / Q000628:therapy; D005260:Female; D006392:Hemangioma, Cavernous / Q000628:therapy*; D006801:Humans; D007231:Infant, Newborn; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D010307:Parotid Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins; D013577:Syndrome; D013921:Thrombocytopenia / Q000628:therapy*
D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins